Founder steps down from CEO role at Beta Bionics

Beta Bionics, a strategic partner of both Novo Nordisk and Zealand Pharma, is making changes to its executive management and board of directors.

Photo: Beta Bionics/PR

Two executives at US-based Beta Bionics, which is partnered with both Novo Nordisk and Zealand Pharma, are switching places.

Former CEO Ed Damiano is stepping down from his executive leadership role, and Martha Goldberg Aronson has been appointed interim CEO until a replacement has been found, a company press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs